Production / Operations Routine +

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Vertically integrated GMP psychedelic manufacturer scaling clinical supply, but revenue remains negligible and execution is incremental.

By The Northwire Desk — AI Analysis Jun 16, 2026 · 08:30 OPTI · 6.89 Optimi Health Corp.

Executive Summary

Optimi Health completed production of 1 mg and 2 mg microdose psilocybin finished drug products.
The new formats are specifically formulated for authorized clinical research organizations to support controlled studies.
The release expands the company's psilocybin portfolio beyond the existing 5 mg capsule currently prescribed in Australia for treatment-resistant depression.
All products are manufactured in-house at the company's GMP-compliant facility in Princeton, British Columbia, under its Health Canada Drug Establishment License.
The company emphasizes validated, consistent dosing compared to traditional dried mushroom microdosing, targeting the accuracy required for clinical research.

Material Impact

The announcement is an operational milestone rather than a commercial or financial inflection point.
No revenue, pricing, contract values, or partnership details are disclosed.
The update directly follows a sequence of similar operational executions: UK Phase 2 trial export (June 10), ibogaine development launch (June 8), and Australian commercial production completion (June 2).
The news confirms ongoing platform development and portfolio expansion but does not alter the company's near-term financial trajectory or valuation.
Market impact is likely muted, as the announcement aligns with previously communicated strategic goals and does not introduce unexpected catalysts.

OPTI · Price

Company Overview

Optimi Health Corp. is a vertically integrated, Health Canada-licensed GMP manufacturer specializing in controlled psychedelic substances, primarily psilocybin and MDMA.
The company operates two 10,000 sq ft facilities in Princeton, British Columbia, capable of biomass cultivation, API extraction, encapsulation, and packaging.
Commercial presence: Supplies psilocybin (5 mg) for treatment-resistant depression and MDMA (40 mg/60 mg) for PTSD in Australia under the Authorized Prescriber Scheme.
Clinical supply: Exports to research institutions globally, including a recent UK Phase 2 trial shipment and upcoming microdose formats for clinical studies.
Strategic expansion: Launching an ibogaine initiative in response to U.S. regulatory shifts, aiming to leverage its Canadian GMP infrastructure for emerging psychedelic therapies.

More from Optimi Health Corp.